Genesis refines test for thrombosis risk
This article was originally published in Clinica
Executive Summary
Genesis Diagnostics has launched a set of two ELISA tests for detecting the risk of thrombosis and embolisms. The tests measure Beta2 glycoprotein-1 IgG and IgM which are thought to be the main markers for the conditions.